Adhera Therapeutics, Inc. (ATRX)
Market Cap | 60.66K |
Revenue (ttm) | n/a |
Net Income (ttm) | -2.53M |
Shares Out | 7.22M |
EPS (ttm) | -0.60 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 25,110 |
Open | 0.0080 |
Previous Close | 0.0081 |
Day's Range | 0.0080 - 0.0084 |
52-Week Range | 0.0011 - 0.0600 |
Beta | 0.25 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About ATRX
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson’s disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana. [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/k/w/press19-1722317.jpg)
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
Baton Rouge, LA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that the Comp...
![](https://cdn.snapi.dev/images/v1/4/a/press14-1549254.jpg)
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist
Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September 8...
![](https://cdn.snapi.dev/images/v1/p/b/press12-1458054.jpg)
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin
Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has...
![](https://cdn.snapi.dev/images/v1/a/l/press2-1382367.jpg)
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointmen...
![](https://cdn.snapi.dev/images/v1/w/q/press16-1286096.jpg)
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board
Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointm...
![](https://cdn.snapi.dev/images/v1/k/d/press6-1193425.jpg)
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its successfu...
![](https://cdn.snapi.dev/images/v1/v/a/press5-1119467.jpg)
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders
Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new Ca...
![](https://cdn.snapi.dev/images/v1/d/q/press19-1094381.jpg)
Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors
Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointme...
![](https://cdn.snapi.dev/images/v1/l/n/press11-1057795.jpg)
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications
Baton Rouge, LA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has...
![](https://cdn.snapi.dev/images/v1/t/1/press10-1051310.jpg)
Manufacturing Commences on Adhera's MLR-1019 for Phase 2a Clinical Trial Treating Parkinson's Disease
IP Estate Grows with New Korean Patent Issued
![](https://cdn.snapi.dev/images/v1/q/e/press13-1033390.jpg)
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new Eu...
![](https://cdn.snapi.dev/images/v1/p/r/press9-1005038.jpg)
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson's Disease and Type 1 Diabetes Drugs
Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an upda...